GLUE Monte Rosa Therapeutics, Inc.

NASDAQ
$8.91

Monte Rosa Therapeutics, Inc. (GLUE) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.0% since its last earnings release on November 5, 2026.

Monte Rosa Therapeutics Beat Consensus Estimates
Thursday, November 5, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.11)
Rev est $44.33M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.